Data resources basics
Using linked electronic health records for translational research The goal of cardiovascular disease (CVD) research using linked bespoke studies and electronic health records (CALIBER) is to provide evidence across different stages of translation, from discovery, through evaluation to implementation where electronic health records provide new scientific opportunities. The expanding role of such record research with clinical and public health impact has been extensively reviewed. [1] [2] [3] [4] With healthy cohort sample sizes Â10 6 and disease registries 10 5 , such records offer a larger scale and higher degree of phenotypic resolution 5 than has been available in investigator led studies.
Opportunity
The UK is the only country in the world that has both detailed electronic primary care records, and CVD and procedure registries at a national scale, as well as more standard sources such as cause-specific hospitalization and mortality records and census data (see Table 1 and Table 2 ). Neither Sweden nor Denmark has comparably rich national primary care data in their respective linkage programmes. Scotland 14, 15 and Wales 16, 17 have established record-linkage programmes that have focused on diabetes and public health research, respectively. Some centres have had prominent research programmes in CVD with a focus on prognosis and quality of care and drug safety research in all phases of translational research in smaller (10 5 ) populations such as the Institute of Clinical and Evaluative Sciences in Canada 18 and Yale, Duke, Intermountain Heart Centre and the Mayo Clinic in the USA. 19 There have been few, if any, attempts to establish an Electronic Health Record (EHR)-based population-based cohort research platform in CVDs.
Who set CALIBER up and how was it funded?
In 2012, the UK Government launched four new centres of EHR research in London, Manchester, Dundee and Swansea. CALIBER is led from the London centre, Centre 21 has led to little information being available on how raw data might be reliably converted into a useable form for researchers, and data inconsistency problems, both of which hinder replication of results and data sharing. (iv) Lack of transparency initiatives, which might address well-recognized problems of selective non-publication, selective reporting and significance chasing biases.
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(v) Data quality has been inadequately tied to the quality of the clinical care received.
CALIBER principles CALIBER was established within CHAPTER, a centre seeking to address these challenges. We set out below our approach for:
Linkage of multiple EHR data sources. (See Table 2 and Figure 1 for key features of five sources of data currently linked in CALIBER.) Linkage with bespoke investigator led cohort studies.
Establishing a common data model with reproducible data variables and meta-data (see Figure 2 and Figure 3) . Transparency-CALIBER studies are registered in the public domain on clinicaltrials.gov, and their analytic protocol is made available for download (see Figure 4) . Emergency, critical care and maternity data not included in CALIBER for now.
DATA RESOURCE PROFILE: CALIBER

Figure 2
The CALIBER framework of transforming raw electronic health record data into usable research-ready data sets the Myocardial Ischaemia National Audit Project (MINAP), 24 Hospital Episodes Statistics (HES) 25 and the Office for National Statistics (ONS) mortality 26 and social deprivation data (Table 2) .
CPRD is a longitudinal primary care data set and records data on symptoms, diagnosis prescriptions, investigations, referrals and vaccinations. Roughly 97% of the population in the UK are registered with a general practitioner (GP). 27 Diagnostic data are coded using Read codes, 28 used in several countries in Europe and which map to Systematic Nomenclature of MedicineClinical Terms. 29 The population of all CPRD practices has been shown to be broadly representative of the population of UK; 23 the subset of practices consenting to data-linkage shares the demographic profile of the full CPRD data set. The CPRD has two key methods of ensuring quality of the data made available to the research community: the 'acceptable research quality' flag, a patient-level quality marker; and the Up To Standard date, a practice-level quality marker.
MINAP is a national registry of patients admitted to 230 hospitals in the UK with acute coronary syndrome (ACS) events. For each admission, MINAP records patient demographic characteristics, limited medical history, clinical features and investigations, drug treatment (pre-, during and post-admission) and final diagnosis, including differentiation into ST elevation MI, non-ST elevation MI and unstable angina.
HES is a national data set of all admissions to National Health Service (NHS) hospitals in the UK. Diagnoses are recorded using the International Statistical Classification of Diseases and HealthRelated Problems, 10th revision (ICD-10) 30 and procedures using the Office of Population Censuses and Surveys Classification of Interventions and Procedures (OPCS) Version 4. 31 The ONS provides data on cause-specific mortality for all residents of the UK. Cause-specific mortality data are extracted from death certificates and recorded using ICD-10. Small-area measures of social deprivation are recorded using the Index of Multiple Deprivation 2007 32 and Townsend scores. 33 Linkage A 10-digit numeric identifier, known as the NHS number, uniquely identifies patients in the UK. Number generation is centrally managed and not derived from demographic information, enabling the identification of patients throughout the NHS in an unambiguous and unique way, making NHS numbers a reliable and robust identifier for record linkage and data sharing while preserving patient confidentiality. Roughly 45% of 592 CPRD practices in the UK consented to linkage of their registered patients. For these participating practices, all patients registered at the practice were included. Following the 'separation principle', 16 data were linked on NHS number, date of birth, sex and post code by a Trusted Party (see Figure 2) .
Measures
Converting raw data to research-ready data: curated common data model Figure 2 illustrates how CALIBER curates data from multiple EHR sources, generating research-ready data from raw data. CALIBER contains 43 billion records of raw data originating from multiple sources. The recorded data are of variable quality, completeness and specificity and unusable for research without proper processing. We have created 4300 variables on medical history, diagnosis, investigations, procedures and prescriptions. Data from all of the source data sets were used in the creation of these variables, and each definition has been reviewed and agreed by both clinical and non-clinical researchers in a transparent and reproducible manner. Coding lists containing Read codes, ICD-10 and OPCS-4 codes were compiled for each variable in a reproducible manner. 34 Variables contain detailed response categories to provide individual researchers with the flexibility to adjust the sensitivity and specificity of their definitions according to their needs.
Variables are curated using established meta-data standards 35 and are versioned using a distributed source control repository system (http://git-scm.com/), which facilitates accurate tracking of changes over time as it keeps all previous revisions of the variables and records the changes between versions. CALIBER researchers have access to the CALIBER online data portal, which includes individual coding lists and programming scripts used to extract both data and clinical coding lists. For each variable, the data portal entry contains the type, source data files, valid range (if applicable), response categories, revision, implementation details and any other relevant information such as references to published literature or descriptive notes. This transparent and reproducible manner of operation ensures that knowledge is fed back into the platform and subsequently becomes available for researchers to make further use of. For example, if a potential researcher is working on an exposure previously not defined within CALIBER, the new variables they define would be incorporated back into the data portal (following peer review) and made available to other future researchers for use.
Metadata enable the automatic generation of the centralized data portal and documentation, keeping the variable definition process synchronized with the research data set creation and curation. Figure 5 illustrates how CALIBER exploits multiple EHR sources to create a robust data variable (CALIBER hypertension). In total, 4700 clinical terms were combined from three EHR sources to create this composite variable, which defines a patient's hypertensive status at a given time point. A patient is considered hypertensive if they have been diagnosed by a GP or within the past year have had at least three measurements of raised systolic or diastolic blood pressure or at least three records of raised blood pressure or at least two prescriptions of blood pressure lowering medication.
CALIBER data include all diagnosed co-existing conditions irrespective of hospital attendance and values of clinically collected circulating biomarkers such as haemoglobin and prescriptions issued, including medication type, timing and quantity. Detailed mental health data on diagnosis and hospitalization for numerous morbidities such as depression, anxiety, bipolar disorder, schizophrenia and psychosis have been included in the data portal (D Batty, personal communication).
Frequency of data collection on patients
Unlike traditional cohorts, in EHR cohorts follow-up is continuous and initiated by capture within one or more EHR source (Figure 1 ). In the example cohort (Figure  3) , the median observation time from study entry date is 5.5 years, with an inter-quartile range (IQR) of 2.1-9.1. Roughly 75.5% of people have at least two blood pressure measurements, and the median number of measurements in people with at least one measurement is 9 (IQR [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The median number of BMI measurements in people with at least one measurement is 3 (IQR 2-7), and similarly the median number of total cholesterol measurements are 3 (IQR 1-6). The mean annual consultation rate at baseline is 7.9.
Biobanks and bespoke cohort linkages
Further linkages have also been established between bespoke investigator led cohort studies and MINAP. Such linkages provide traditional cohort studies with higher-resolution ACS endpoints. Specifically, we have coordinated the linkage between MINAP and (i) the UK Collaborative Trial of Ovarian Cancer Screening, a randomized trial of 200 000 post-menopausal women aged 50-74 years; 36 (ii) Whitehall II, a cohort of $10 000 civil servants aged 35-55 years; 37 and (iii) UK Biobank, a cohort of 500 000 middle-aged adults with a range of physical measurements and biological samples. 38 Cross-referencing of acute myocardial infarction in four sources is under way.
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Data resource use
One important use is to define cohorts using the primary care as denominator population. An example of such a CALIBER cohort (entry between years 2001-10) is shown in Figure 3 . The sample consists of 901 629 adults aged 530 years (39.54% men) registered with a CPRD practice, which participates in the data linkage and that have data of acceptable research quality, no prior atherosclerotic disease and complete baseline data on age, sex, blood pressure, smoking, diabetes status and lipid lowering medication information. CALIBER resources are contributing new knowledge at different stages in translational pathways, e.g.:
Risk factors for initial presentation of CVDs: CALIBER cohorts allow investigation of initial presentation of a wide range of CVDs, which has hitherto not been possible in smaller, less-well clinically phenotyped cohorts. For example smoking has heterogeneous associations with different CVD endpoints, with no association with initial presentation with ventricular arrhythmia or cardiac arrest, a modest association with chronic stable angina and heart failure and strong associations with ACSs. 39 Prognosis: A new prognostic model for people with stable coronary artery disease (CAD) 40 has been developed and validated in a population of 100 000 patients with stable angina or who have become stable after an ACS. We show that clinically collected information, including biomarkers, provides significant improvements in discrimination, risk reclassification and clinical cost-effectiveness beyond that achieved based on age, sex, CAD type and clinical history alone. Quality of care and outcomes research: Two countries in the world have MI registries, which include data on consecutive patients in all hospitals. In comparisons of over half a million patients in Sweden and the UK, there were important treatment differences, and the 30-day mortality was lower in Sweden. 41 Pharmacoepidemiology: Although primary care data have long been used for pharmacoepidemiology, new CALIBER linkages with hospital event data from MINAP and HES allowed CALIBER to contribute new policy-relevant evidence on the potential harms of clopidogrel discontinuation 42 and the lack of robust evidence of interaction between clopidogrel use and proton pump inhibitors. 43 
Figure 5
Example of one CALIBER research variable, hypertension, created from multiple raw electronic health record sources. The variable uses a combination of (i) repeat continuous blood pressure measurements; (ii) categorical data on measured blood pressure (over 130 Read codes); (iii) hypertension diagnosis in primary care (over 180 Read codes); and (iv) prescription of blood pressure lowering medications
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Future developments
The data resources accessible via CALIBER will grow in CHAPTER in several respects including increasing the scale of population coverage to design and implement randomized trials within the primary care record and within disease and procedure registries (NICOR), to incorporate bioresources allowing genomic approaches to discovery and to use natural language processing of text recorded in primary care. Planned extensions include wider coverage of primary care data (current linked CPRD data cover 8% and aims to include 25% by end of 2012, maximizing the coverage by March 2016) and linkage with wider disease and procedure registries in NICOR. A key next step is to incorporate linkages with integrated hospital records and integrate clinical research with medical care on a large scale by unlocking the full potential of data collected in such settings. Existing platforms such as the National Institute for Health Research Cardiovascular Biomedical Research Unit, an integrated cardiovascular hospital records platform spanning cardiac data, general trust-level systems, radiology and genomics systems for 25 000 patients will be expanded.
Strengths and weaknesses
CALIBER has potential strengths in the degree of clinical, longitudinal phenotyping spanning ambulatory and hospitalized care in large population samples. This allows opportunities for a 'higher resolution' approach to cardiovascular epidemiology in three respects. First, most existing investigator led (bespoke) cardiovascular cohorts study broad aggregates [CVD, coronary heart disease (CHD)], or at most distinguish a narrow range (typically two or three) of different diseases of interest. As the causes, treatment and prognosis vary across a range of disease phenotypes, CALIBER data sets have the statistical size and clinical phenotyping allowing the opportunity to 'resolve' these broad aggregates into distinct disease phenotypes in cerebral, peripheral and coronary circulations. Figure 3 illustrates that cardiac diseases include the following: chronic stable angina, unstable angina, ST elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), heart failure, ventricular arrhythmias and cardiac arrest, sudden cardiac death and unheralded coronary death. Use of four sources of data to define endpoints is illustrated in Appendix A. Second, unlike many investigator led cardiovascular cohorts, CALIBER data sets have the temporal resolution to distinguish whether a first event (e.g. heart attack or stroke) was the first manifestation of CVD or whether it was preceded by any of a range of non-fatal (and often diagnosed in primary care) manifestations of CVD. Third, most previous studies have been too small to understand the interplay between different causal domains. For example, even addressing the simple question of gender differences in the smoking effect across different specific cardiovascular endpoints necessitates large samples. CALIBER cohorts have a sufficient number of events and patients on which accurate estimates of risk can be based.
The main weaknesses of any EHR research platform relate to data quality.
Data quality in single sources
Data quality in single sources requires evaluation on a case by case basis with a range of methods: crossreferencing against chart review, against data collected under research conditions and cross-sectional and prospective tests of validity.
Missing data
Although some measurements, such as BMI, are reasonably complete (82.6% of people with at least one BMI measurement), others, such as total cholesterol, are less complete (44.9% with at least one total cholesterol measurement). Developments in imputation of missing data within such primary care longitudinal cohorts are promising and might offer a partial solution to the problem. 44 Variation in coding used across practices and over time, as well the use of broader diagnostic categories used (e.g. CHD Not Otherwise Specified), 45 may prove more difficult to resolve.
Conflicting data
Fatal MI may be recorded in up to four different sources, which differ in their diagnostic granularity and timing accuracy. Multiple records at similar time points may reflect the same event or subsequent events-e.g. an MI is recorded in CPRD, and, after 30 days in MINAP, could point to a single or recurrent event (E Herrett, personal communication).
Linkage quality
There is empirical evidence 46 that errors in data linkage can lead to significantly different conclusions about the associations of risk factors with outcomes. The linkage method used for linking CALIBER constituent data sets has been used before, and it has been shown to yield reasonably high quality matches.
Data resource access
Raw data are available for use by researchers subject to approval of the protocol by, and payment to, the bodies governing access to the constituent data sets. For CPRD, this involves scientific approval of the protocol by the Independent Scientific Advisory Committee and a signed licence outlining scope and data confidentiality of use of CPRD data. For MINAP, applications are made to the MINAP Academics Group, and to the NHS Information Centre 47 for HES and ONS. Following such approvals, an application to the CALIBER Scientific Advisory Committee should be submitted. DATA RESOURCE PROFILE: CALIBER CALIBER researchers register their study and publish their protocol in the public domain before receiving data. 48 Study registration and protocol publication are of complementary nature; registration records present short, standardized elements of the full protocol in an accessible manner.
CALIBER welcomes collaborative research. Access to data for external researchers (those who are not affiliated with CALIBER investigators) is provided within the CALIBER 'safe haven' environment, which currently requires researchers to be physically based in either UCL (Clinical Epidemiology Group) or the London School of Hygiene and Tropical Medicine (Smeeth). Given the diverse clinical origins, complexity and size of the data sets, training with the CALIBER team on data sources, coding, quality and management is available.
The CALIBER data portal is available for consultation online at http://www.caliberresearch.org/. Existing and potential collaborators are encouraged to provide feedback on potential enhancements to the portal to facilitate the wider use of these data resources.
For more information, visit http://www.caliber research.org/ or contact Dr Spiros Denaxas at s.denaxas@ucl.ac.uk.
